My mhealth and their NHS partners announce the national rollout of myAsthma Biologic a digital therapeutic designed to support patients with severe asthma

BRISTOL, 24th November 2022 – The NHS is facing unprecedented pressures this winter, and it is anticipated that patients with respiratory disease may occupy up to half of all hospital beds. It is therefore vital that the management of patients with Severe Asthma, who are at high risk of hospitalisation, is optimised.  

In this context, the Accelerated Access Collaborative (AAC), Academic Health Sciences Network (AHSN), my mhealth Limited and University Hospitals Southampton (UHS) are pleased to announce the launch of myAsthma Biologic, an extension to my mhealth’s existing myAsthma product, which will support 10,000 patients with severe asthma on biologic therapy across the United Kingdom.

Over the last few years, the administration of biologic therapy has moved from the clinic, into the home. This is far more convenient for patients, who in many cases had to travel hundreds of miles to receive their treatment because it is only offered in a few specialist centres. myAsthma Biologic was commissioned as part of the NHS AAC Rapid Uptake Products programme, which aims to improve access to biologic therapies by improving pathways and current practices to achieve timely specialist patient care. The digital therapeutic supports patients in managing their asthma, and their clinical teams in managing and monitoring them remotely.

This exciting new product will also facilitate standardised and timely collection of clinical data through automated upload to the national severe asthma registry. Through the programme, sites currently inputting data in the severe asthma registry and prescribing asthma biologics will have access to myAsthma Biologic.

Simon Bourne, Company President at my mhealth comments “As a respiratory focussed digital therapeutics company, we are honoured to have been chosen to roll out our product nationally to better support patients on biologics, who are living with Severe Asthma. We have already seen the huge potential of digital therapeutics to improve patients’ symptoms and quality of life and deliver efficiencies across primary and community health care services, and look forward to working with the specialist severe asthma centres across the UK.’’

Professor James Dodd, clinical lead North Bristol’s complex airways service added, “The Bristol severe Asthma service is delighted to be part of this national project to adopt and evaluate the myAsthma Biologic App. With the growing number of highly effective monoclonal antibody therapies, and the growing demand on our services, we believe that digital therapeutics like myAsthma Biologic will be increasingly important. Digital innovation has the potential to complement our dedicated multi-disciplinary team to increase capacity and enhance the support patients need to keep them well.”

About my mhealth

my mhealth’s digital therapeutics have been prescribed to over 90,000 patients with chronic conditions, resulting in reduced morbidity and hospital admissions. It serves pat 
patients across a range of long-term conditions, including COPD, asthma, diabetes and cardiovascular disease. Real world and clinical trial evidence demonstrates the efficacy of digital interventions on the my mhealth platform. For more information on my mhealth, visit www.mymhealth.com. 

Show More